Eagle Pharmaceuticals Inc.

Address: 50 Tice Boulevard Suite 315

Sponsor Overview

assignment

Specializations

Infectious Disease and Severe Community-Acquired Bacterial Pneumonia

Eagle Pharmaceuticals Inc. is focused on clinical research in severe community-acquired bacterial pneumonia (SCABP), with attention to treatment options for serious bacterial lung infection requiring hospital-based care.

Severe bacterial pneumonia
Community-acquired respiratory infection
Clinical recovery

The sponsor’s research interest in this area centers on improving outcomes in patients with advanced respiratory infection and evaluating treatment approaches alongside standard of care.

Anti-Infective Therapeutics

The clinical program includes interest in therapies aimed at supporting recovery in bacterial pneumonia, with emphasis on agents intended to address the inflammatory and clinical burden associated with severe infection.

Adjunctive pneumonia therapy
Supportive treatment in infection
Respiratory infection management

Research activity in this domain reflects a therapeutic focus on infection-related hospital medicine and the management of acute pulmonary disease.

Safety and Tolerability in Acute Care

Clinical evaluation also addresses the safety and tolerability of investigational treatment in patients with serious infection, with relevance to medically vulnerable populations treated in acute settings.

Adverse event monitoring
Acute hospital care
Patient tolerability

This area is closely tied to the practical use of therapies in severe infectious disease and the clinical management of hospitalized patients.

Trial Name	Country	Status
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CAL02 ADMINISTERED INTRAVENOUSLY IN ADDITION TO STANDARD OF CARE IN SUBJECTS WITH SEVERE COMMUNITY-ACQUIRED BACTERIAL PNEUMONIA (SCABP)	Belgium Czechia France Greece Hungary Latvia Romania Slovakia Spain	Not Yet Recruiting